ELN...here's what one newsletter wrote yesterday....
ELN – Still consolidating on huge volume. I’ve read and re-read everything and I think this sell-off is absurd. The market is currently pricing in a complete loss of Tysabri for the treatment of MS and I don’t even see that as a remote possibility (Some analysts say 50%, etc.. I think their full of it and just trying to cover their own A$$). I think it’s just a matter of time before more data is revelaed regarding the patient death and I believe that there will be no findings of a correlation between Tysabri and the death. It’s either a problem with the combination of both drugs, or simply an incident in which the disease progressed beyond control. Not everyone reacts to the same medication in the same way.
Market Data 
Markets 
AI
